Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.90 -0.18 (-0.30%)
Official Closing Price Updated: 7:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
42 43 Next >
Why Bristol Myers' Shares Are Trading Higher Today
Bristol Myers Squibb & Co (NYSE: BMY) has received positive CHMP opinion for Opdivo (nivolumab) plus chemotherapy for first-line treatment of unresectable advanced,... 
Via Benzinga
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY) to... 
Via Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
Photo by National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing... 
Via Benzinga
7 New ETFs To Consider if You Want To Play Today’s Top Trends
These recently-launched ETFs offer diversification as well as the opportunity to benefit from the emerging industries and trends. 
Via InvestorPlace
Holiday Over
China is busily avoiding taking sides between Ukraine and Russia. 
Via Talk Markets
Golden Cross Appears Before Bristol-Myers Squibb Investors
If history is any guide, there may be good fortune ahead for shares of Bristol-Myers Squibb (NYSE:BMY). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Drug Giant Bristol-Myers Squibb Stock Sees Composite Rating Climb To 96
Bristol-Myers Squibb stock saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 94 the day before. 
Via Investor's Business Daily
Will Investors Notice Exciting Sign On Bristol-Myers Squibb's Chart?
If history is any guide, there may be good fortune ahead for shares of Bristol-Myers Squibb (NYSE:BMY). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative Colitis
Bristol Myers Squibb & Co (NYSE: BMY) has announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Whale Trades Spotted
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy
Bristol Myers Squibb Co's (NYSE: BMY) VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM) met its... 
Via Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (... 
Via Benzinga
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
From Bristol Myers Squibb
Via Business Wire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
Nuclear Winter
Mexico is raising interest rates to 6%, from 5.5%. 
Via Talk Markets
Daily Report: Bristol - Myers Squibb (BMY)
Bristol's price per share was $66.50 as of yesterday's market close. One year ago its price was $59.99. 
Via Talk Markets
6 Companies That Recently Announced Large Buybacks
There are several ways that a company can return wealth to its shareholders. Price appreciation and dividends are the two most common ways, but there are other ways a company... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.